AI assistant
Sending…
Actinium Pharmaceuticals, Inc. — Director's Dealing 2016
Apr 18, 2016
34570_dirs_2016-04-18_ba7b8f79-d6dd-4a9b-b4ff-b8d35c3175a0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2016-04-14
Reporting Person: Nicholson, C. David (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-04-14 | Common Stock | P | 5000 | $2.00 | Acquired | 15000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-04-15 | Options to purchase common stock | $1.99 | A | 75000 | Acquired | 2026-04-15 | Common Stock (75000) | Direct |
Footnotes
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.
More from Actinium Pharmaceuticals, Inc.
Regulatory Filings
2026
May 29
Annual Report
2026
Mar 30
Declaration of Voting Results & Voting Rights Announcements
2026
Mar 26
Board/Management Information
2026
Feb 13
Declaration of Voting Results & Voting Rights Announcements
2025
Nov 26
Interim / Quarterly Report
2025
Nov 14
Annual Report
2025
Nov 5
Proxy Solicitation & Information Statement
2025
Nov 5
Director's Dealing
2025
Aug 20
Interim / Quarterly Report
2025
Aug 8